Literature DB >> 999556

Adenocarcinoma of eccrine sweat glands.

W S Grizzard, E Torezynski, W C Edwards.   

Abstract

A man developed left-sided proptosis and orbital edema that progressed during a three-week period. Ten years ago he had a skin lesion of the left lower lid excised and the histopathologic diagnosis then was granular cell myoblastoma. In 1972, the tumor recurred; a biopsy was again performed, but no definite diagnosis was made despite multiple consultations from general and ophthalmic pathologists. Biopsy specimens of the orbit, lids, and preauricular lymph node taken in 1974 showed a poorly differentiated mucus-secreting adenocarcinoma. A comparison of the three biopsy specimens showed cells with similar characteristics. Medical evaluation failed to reveal a primary tumor elsewhere in the body. The tumor most likely arose locally from an eccrine sweat gland. This is the second reported case of an adenocarcinoma of an eccrine sweat gland invading the orbit. The tumor, usually considered radioresistant, was successfully treated with radiotherapy, and the patient has remained free of tumor for 18 months.

Entities:  

Mesh:

Year:  1976        PMID: 999556     DOI: 10.1001/archopht.1976.03910040779012

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Eyelid tumors of sweat gland origin.

Authors:  M Lahav; D M Albert; R Bahr; J Craft
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

2.  Diagnostic and treatment challenges of a case of primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid.

Authors:  Mathew M Palakkamanil; Muhammad N Mahmood; Audrey Chan
Journal:  BMC Ophthalmol       Date:  2020-10-14       Impact factor: 2.209

3.  Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents.

Authors:  Lei-Chi Wang; Tai-Chi Lin; Yi-Chen Yeh; Hsiang-Ling Ho; Chieh-Chih Tsai; Teh-Ying Chou
Journal:  Curr Oncol       Date:  2021-02-16       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.